The proportion of Malaysian mothers who are positive for HBsAg remains high. The three-shot hepatitis B vaccine, given as part of universal vaccination against hepatitis B, provides adequate anti-HBs in the vast majority of infants in a community setting in Malaysia.
INTRODUCTION
programmes. (2) Various studies have shown that immunisation in infancy provides adequate protection against HBV infection, which lasts even till school-going age. (3) However, studies have also found that not every recipient of the vaccine produces adequate protective levels of the antibody after completion of primary immunisation. (4) In Malaysia, universal hepatitis B vaccination of all newborn infants has been implemented since 1989. However, to the authors' knowledge, only one industry-sponsored study has ever assessed the seroprotective anti-hepatitis B antibody (anti-HBs) levels in a setting where hepatitis B vaccines were given in combination with other childhood vaccines. 
METHODS
The present study was conducted among infants who attended (Table I ). The majority of infants (13/14) delivered to HBsAg-positive mothers had adequate antibody levels. None of the infants in our group was found to be HBsAg-positive.
DISCUSSION
Universal hepatitis B vaccination is known to bring enormous benefits to communities where HBV infection is endemic.
(1)
Hepatitis B vaccination has been associated with the elimination or reduction of childhood hepatocellular carcinoma, (7) acute liver failure (8) and, more recently, virus-associated membranous nephropathy. (9) Universal hepatitis B immunisation of newborns has been implemented in Malaysia since 1989. (10) Since then, there has been a steady decline in the seroprevalence of HBsAg -from 2.5% for children born in 1985 (four years before universal immunisation) to 0.4% among school children born in 1996. (10) The results of the present study show that universal hepatitis B vaccination of newborns in Malaysia is highly successful. 96.7%
of the 572 infants immunised in our study were found to have adequate levels of anti-HBs at approximately one year of age.
Furthermore, none of the 14 infants who were born to HBsAgpositive mothers were found to be HBsAg-positive. Among these 14 infants, 13 were found to have adequate levels of protective anti-HBs following immunisation. Failure to produce detectable antibody levels even after three doses of hepatitis B vaccines has been reported in a small minority of patients. (11) Researchers have adopted various methods to overcome this problem, including administering a fourth dose of vaccine (11) or a booster dose at a later age. (3) However, it should be noted that the risk of acquiring HBV infection among non-responders has been found to be similar to that among those given booster vaccines.
The present study also found that chronic HBV infection 
One of the potential drawbacks of the present study was the lack of information on the status of hepatitis B e antigen (HBeAg) among women who were HBsAg positive, as it is well known that vertical transmission is more likely to occur among infants born to women who are positive for both HBeAg and HBsAg. (12) In conclusion, the proportion of 
